---
title: "Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294510325.md"
description: "Moleculin Biotech reported interim data from the MIRACLE trial showing a 37% complete remission rate in venetoclax-failed AML patients. No cardiac toxicity signals were observed. Enrollment reached 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded results anticipated between December 2026 and February 2027."
datetime: "2026-07-31T12:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294510325.md)
  - [en](https://longbridge.com/en/news/294510325.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294510325.md)
generator: "portal-rs"
---

# Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients

-   Moleculin Biotech reported updated interim data from Part A of its pivotal MIRACLE trial in relapsed or refractory acute myeloid leukemia. \* Results have been disclosed now in a blinded analysis; comprehensive unblinded Part A results are expected in the December 2026 to February 2027 window. \* Patients who previously failed venetoclax showed remission outcomes broadly consistent with the overall study population. \* The company continued to report no signal of cardiac toxicity, supporting its differentiation from standard anthracyclines. \* Enrollment reached 74 of 90 patients; the final Part A treatment is expected in September 2026, a key step toward advancing the program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025167), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech says AACR pancreatic cancer conference features new Annamycin trial data](https://longbridge.com/en/news/298919395.md)
- [Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings | MBRX Stock News](https://longbridge.com/en/news/298919863.md)
- [Moleculin Biotech highlights interim Phase 3 AML data for annamycin showing 36% CR, 54% CRc in pooled arms](https://longbridge.com/en/news/297668239.md)
- [Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand | MBRX Stock News](https://longbridge.com/en/news/298734223.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**